| Revenue growth | FY26: 6.9% YoY; Q4FY26: 6.1% YoY. |
|---|---|
| Margins | Structural improvement; EBITDA margin expanded ~560 bps from FY24 to FY26. |
| Demand visibility | Broad-based momentum across key global regions like Europe and LATAM. |
| Management confidence | High; confident in high single-digit growth for FY27. |
Growth
FY26 revenue grew 6.9% to ₹25,518 Mn; EBITDA surged 19.6% to ₹8,577 Mn with margins at 33.6%.
Outlook
FY27 guidance: high single-digit revenue growth and 30%+ margins. Total capacity to double to 2,690 KL by FY28.
Risks
GPL business de-grew 4.9%; higher working capital at 199 days; tariff and supply chain uncertainty noted.
Earnings Call filed with BSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,365.60
- Market cap
- ₹16,766 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 27.8×Sector 50.4×
- Promoter holding
- 74.87%+0.00% QoQ
- FII holding
- 5.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Earnings Call Transcript: Key Takeaways
Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.
- Call
- Guides 11% growth
Alivus Life Sciences Investor Presentation: Key Takeaways
Alivus Life Sciences delivered strong Q1FY27 performance with revenue at ₹6,404 Mn and EBITDA margins expanding to 36.6%. The company is pivoting towards Non-GPL segments and CDMO growth.
- Call
- Guides 11% growth
Alivus Life Sciences Q1 FY27 Results: Net Profit ₹160.1 Cr, Up 31.8% YoY
Alivus Life Sciences Ltd reported revenue from operations of ₹640.4 Cr (+6.4% YoY) and net profit of ₹160.1 Cr (+31.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹160.1 Cr · +31.8% YoY
Alivus Life Sciences Earnings Call: Key Takeaways
Alivus (ex-Glenmark Life Sciences) reported strong Q4FY26 results with record 33.6% EBITDA margins, driven by non-GPL growth (71% of business) and CDMO recovery.